Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2010 in Advanced Solid Tumors
NCT07793942Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of MK-2010 in solid tumor (7 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with Adverse Events at 24 months, Number of Participants Who Discontinue Study Treatment Due to an AE at 24 months and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
MK-2010
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07793942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793942.